Bellini C, et al. - Authors evaluated the effectiveness and safety of octreotide (a somatostatin analogue) in the treatment of congenital and acquired chylothorax in newborns. They noted the most common therapeutic scheme to be intravenous infusion at a starting dose of 1 μg/kg/h, gradually increasing to 10 μg/kg/h depending on the therapeutic response. As per the findings, in neonates with chylothorax, especially for the congenital forms, octreotide was a relatively effective and safe treatment option.